Citadel Advisors’s DIPLOMAT PHARMACY, INC. DPLO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q4 | – | Sell |
-20,600
| Closed | -$101K | – | 10125 |
|
|
2019
Q3 | $101K | Buy |
20,600
+3,400
| +20% | +$19K | ﹤0.01% | 8481 |
|
|
2019
Q2 | $105K | Sell |
17,200
-76,700
| -82% | -$408K | ﹤0.01% | 8519 |
|
|
2019
Q1 | $546K | Buy |
+93,900
| New | +$970K | ﹤0.01% | 6646 |
|
|
2018
Q3 | – | Sell |
-9,900
| Closed | -$253K | – | 9961 |
|
|
2018
Q2 | $253K | Sell |
9,900
-10,200
| -51% | -$238K | ﹤0.01% | 7510 |
|
|
2018
Q1 | $405K | Buy |
20,100
+3,700
| +23% | +$86.3K | ﹤0.01% | 6254 |
|
|
2017
Q4 | $329K | Buy |
+16,400
| New | +$323K | ﹤0.01% | 6305 |
|
|
2017
Q2 | – | Sell |
-17,500
| Closed | -$279K | – | 8351 |
|
|
2017
Q1 | $279K | Buy |
+17,500
| New | +$252K | ﹤0.01% | 5986 |
|
|
2016
Q2 | – | Sell |
-7,700
| Closed | -$211K | – | 7688 |
|
|
2016
Q1 | $211K | Sell |
7,700
-6,900
| -47% | -$203K | ﹤0.01% | 5576 |
|
|
2015
Q4 | $500K | Buy |
14,600
+600
| +4% | +$18.7K | ﹤0.01% | 4475 |
|
|
2015
Q3 | $402K | Sell |
14,000
-12,300
| -47% | -$526K | ﹤0.01% | 5118 |
|
|
2015
Q2 | $1.18M | Buy |
26,300
+16,000
| +155% | +$602K | ﹤0.01% | 3751 |
|
|
2015
Q1 | $356K | Buy |
+10,300
| New | +$280K | ﹤0.01% | 5415 |
|
Other funds holding DPLO
Citadel Advisors's DPLO Position: Q1 2020 in Review
Citadel Advisors sold out of DIPLOMAT PHARMACY, INC. (DPLO) in Q1 2020, closing a stake of 20,463 shares — an estimated $82K sold.
Citadel Advisors first reported a position in DPLO in Q1 2015 and held it in 16 quarters. The position peaked at $27.5M in Q1 2017. 1 fund tracked by Wall St. Rank holds DPLO as of Q1 2020.
- Citadel Advisors reported no remaining DIPLOMAT PHARMACY, INC. position as of Q1 2020 after selling out during the quarter.
- Citadel Advisors sold 20,463 DIPLOMAT PHARMACY, INC. shares in Q1 2020, an estimated $82K.
- Citadel Advisors first reported a position in DIPLOMAT PHARMACY, INC. in Q1 2015 and held it in 16 quarters.
- Citadel Advisors's DIPLOMAT PHARMACY, INC. position peaked at $27.5M in Q1 2017.
- 1 fund tracked by Wall St. Rank held DIPLOMAT PHARMACY, INC. as of Q1 2020.
Based on Citadel Advisors's 13F filing for Q1 2020, filed 15 May 2020.